Sheth KN, et al. - In this phase II GAMES-RP Study, experts aspired to explore whether subjects aged ≤70 years who were treated with intravenous glyburide (RP-1127; BIIB093; glibenclamide) would have better long-term outcomes than those who received placebo. They recruited 86 members, aged 18 to 80 years, who presented to 18 centers with large hemispheric infarction randomized within 10 hours of symptom onset. After acute therapy with intravenous glyburide, participants ≤70 years of age with large hemispheric infarction had improved survival.